We have built a team with deep experience in diagnostics including commercialization, reimbursement, regulatory, medical affairs, research and development, technology, and operations to provide the needed products and services to address critical clinical questions and help improve patient care.

Biodesix Mission:  Our mission is to transform patient care and improve outcomes through personalized diagnostics that are timely, accessible and address immediate clinical needs.

Biodesix Vision:  We envision a world where patient diseases are conquered with the guidance of personalized diagnostics.

Sadly, each year, there are more Americans that die from lung cancer than the next 3 cancers combined:  breast, colorectal, prostate.

• Only 27% of lung cancers are diagnosed at an early stage of the disease
• There's an 8x greater survival with lung cancer can be diagnosed at an early stage, such as lung nodule presentation
• 80% of 8-30mm lung nodules have intermediate risk and are frequently over-and under-treated

We are honored to be recognized with the following:

2024

• Inc. Magazine – Best Workplaces 2024
• Healthcare Technology Report – Top 100 Healthcare Technology Companies
• Newsweek – World’s Best Digital Health Companies of 2024
• Smart Business Dealmakers – Scott Hutton, CEO Biodesix, Dealmaker of the Year Honoree
• Healthcare Technology Report – Scott Hutton, CEO Biodesix, Top 25 Executives in Biotech
• Denver Business Journal – Robin Cowie, CFO Biodesix, Top CFO nominee
• BizWest - Innovation Quotient (IQ) award finalist for Biodesix VeriStrat and GeneStrat lung cancer treatment guidance tests
• Frost & Sullivan - Best Practices in Diagnostics

2023

• BizWest – The Region's 500 Largest and Fastest Growing Companies (#18 in public companies)
• Healthcare Technology Report – Power 500 Healthcare Technology Companies of 2023 (#334)

2022

• Life Sciences Review - Top Proteomics Company in the US

Biodesix, Inc. headquarters are in Louisville, CO.

Laboratory locations:  Louisville, CO and DeSoto, KS